Healthcare Research of Top Gainer Stocks (BSX, JNJ, DVAX, PFE, ARNA)

Los Angelas, CA -- (SBWIRE) -- 11/20/2012 -- Boston Scientific (NYSE:BSX) traded up 1.36% during mid-day trading on Monday, hitting $5.21. Boston Scientific has a one year low of $4.79 and a one year high of $6.41. The company’s market cap is $7.153 billion. Boston Scientific last issued its quarterly earnings data on Thursday, October 18th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.11 by $0.63. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. Analysts expect that Boston Scientific will post $0.41 EPS for the current fiscal year.

Can BSX Continue To Move Higher? Find out Here

Johnson & Johnson (NYSE:JNJ) has announced an ex-dividend date of November 23, 2012 and a cash dividend payment of $0.61 per share scheduled for December 11, 2012. Shareholders who purchased JNJ stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that JNJ has paid the same dividend. At the current stock price of $69.25, the dividend yield is 3.52%. The previous trading day's last sale of JNJ was $69.25, representing a -4.8% decrease from the 52 week high of $72.74 and a 13.43% increase over the 52 week low of $61.05.

Can JNJ Jump Again? Find Out Here

Dynavax Technologies Corporation (NASDAQ:DVAX) shares for any reason plummet below $2.50 prior to January expiration. The stock had an after-hours print off a bit below $1.70 following the FDA panel vote so that can act as the initial downside risk target for a catastrophic scenario. If the shares trade a bit lower than $2.50 by expiration, we maintain the option to be assigned the shares with a perfect follow-on trade of selling the February 2.5 strike Calls against the long stock position. These expire prior to the Feb. 24 FDA decision date, thus are a great way to play a covered Call.

Can DVAX Continue To Rise? Find Out Here

Pfizer Inc. (NYSE:PFE) is off 0.29 percent to $24.07 today after bouncing off support around $23.50 at the end of last week. But the gains of the last two sessions took the stock only back to where it was a week ago. Shares have been declining from a five-year high of $26.09 set for Oct. Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition.

Can PFE Extend Gain? If Yes, How Far It Can Go? Find Out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), with its very weak revenue results, has greatly underperformed against the industry average of 5.7%. Since the same quarter one year prior, revenues plummeted by 57.1%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share. The net income growth from the same quarter one year ago has greatly exceeded that of the S&P 500, but is less than that of the Biotechnology industry average. The net income increased by 31.7% when compared to the same quarter one year prior, rising from -$22.74 million to -$15.52 million.

How Should Investors React To ARNA Now? Find Out Here

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com